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Functionality of the putative surface glycoproteins
of the Wuhan spiny eel influenza virus
Guha Asthagiri Arunkumar 1,2, Disha Bhavsar1, Tiehai Li3, Shirin Strohmeier1, Veronika Chromikova1,
Fatima Amanat 1,2, Mehman Bunyatov4, Patrick C. Wilson 5, Ali H. Ellebedy 6, Geert-Jan Boons3,4,
Viviana Simon 1, Robert P. de Vries4 & Florian Krammer 1✉
A panel of influenza virus-like sequences were recently documented in fish and amphibians.
Of these, the Wuhan spiny eel influenza virus (WSEIV) was found to phylogenetically cluster
with influenza B viruses as a sister clade. Influenza B viruses have been documented to
circulate only in humans, with certain virus isolates found in harbor seals. It is therefore
interesting that a similar virus was potentially found in fish. Here we characterize the putative
hemagglutinin (HA) and neuraminidase (NA) surface glycoproteins of the WSEIV. Func-
tionally, we show that the WSEIV NA-like protein has sialidase activity comparable to B/
Malaysia/2506/2004 influenza B virus NA, making it a bona fide neuraminidase that is
sensitive to NA inhibitors. We tested the functionality of the HA by addressing the receptor
specificity, stability, preferential airway protease cleavage, and fusogenicity. We show highly
specific binding to monosialic ganglioside 2 (GM2) and fusogenicity at a range of different pH
conditions. In addition, we found limited antigenic conservation of the WSEIV HA and NA
relative to the B/Malaysia/2506/2004 virus HA and NA. In summary, we perform a func-
tional and antigenic characterization of the glycoproteins of WSEIV to assess if it is indeed a
bona fide influenza virus potentially circulating in ray-finned fish.
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Influenza A and B viruses cause widespread infections inhumans on an annual basis resulting in significant morbidityand mortality1. In addition to human infections, influenza A
virus has been shown to have a broad host tropism, infecting a
variety of different avian and mammalian species2. This enhances
the pandemic potential of these viruses due to an increased
possibility of reassortment in a commonly infected host3. In
contrast, influenza B viruses have a comparatively limited host
range comprising predominantly of infections in humans.
Sporadic outbreaks have been observed in harbor seals and gray
seals, and this has brought into question the possibility of non-
human reservoirs for influenza B viruses4,5. However, sequence
analysis of influenza B virus isolates from seals suggests that the
causative agents were human strains6. Partial sequences of iso-
lates of influenza B viruses identified in swine farms across the
USA displayed high homology to human influenza B virus iso-
lates as well7. Overall, studies have documented spillage of
influenza B virus infections from humans to other species,
however, there is limited evidence for the existence of sustained
animal reservoirs for these viruses.
The overall understanding of RNA virus diversity outside of
avian and mammalian species has been limited stemming from
sampling biases towards these hosts8. A study by Shi et al. aimed
at addressing this dearth of sampling in amphibians, fish, and
reptiles, and identified 214 vertebrate species-associated virus
sequences through a meta-transcriptomic approach. Most of
these viruses could be categorized into 17 vertebrate-specific viral
families, significantly enhancing the diversity of viral families
historically known to have mammalian or avian hosts. Three
novel influenza viruses were identified in ray-finned fish (spiny
eel), jawless fish (hagfish), and amphibians (Asiatic toad). These
were the first documented sequences of putative influenza viruses
in fish9.
For the Wuhan spiny eel influenza virus (WSEIV), all eight
genomic segments were recovered following the sampling and
analysis of the transcripts in the gill tissues of lesser spiny eels
(Macrognathus aculeatus). A striking aspect of this virus is its
phylogenetic clustering as a sister clade to influenza B viruses,
more so than influenza A viruses do. Alignment of the coding
regions of the eight segments of WSEIV indicates percentage
identity as high as 76% (PB1) and as low as 34% (NS) with
the closest hits all being in the influenza B virus species. The
surface viral glycoproteins, hemagglutinin (HA), and the neur-
aminidase (NA) of the WSEIV have a 45% and 48% amino acid
identity to the respective HA and NA of influenza B viruses9.
Given our interest in studying viral glycoproteins, we decided
to take a deeper dive into characterizing the HA and NA of the
WSEIV and their influenza B virus counterparts. This could
provide valuable insight into this novel influenza B-like virus, and
its implication of non-human reservoirs for influenza B viruses.
Additionally, influenza B viruses are largely understudied relative
to influenza A viruses in the context of the functionality and
antigenic landscape, and the findings from this study contribute
towards addressing this gap10. The questions raised during the
conception of this study were as follows. Does the WSEIV HA
have sialic acid-binding activity and what receptor specificity does
it possess? Does the WSEIV neuraminidase have sialidase enzy-
matic activity? How do the functional and antigenic aspects of
these proteins compare to those of influenza B virus HAs and
NAs and how does this inform the potential of this virus to spill
over into humans?
Here, we demonstrate that the WSEIV HA and NA show
opposing similarity profiles relative to influenza B/Malaysia/2506/
2004 virus HA and NA. The WSEIV HA appears to strongly
interact with a unique gangliosidic receptor, displaying drastically
different target receptor specificity compared to influenza B virus
HAs. Additionally, we show that the WSEIV HA can be activated
by trypsin, but not any human airway proteases, and it is fuso-
genic. Taken together, the WSEIV HA interacts with a sialic acid-
containing receptor, can be activated by a protease, and can
mediate fusion. On the contrary, the WSEIV NA, showing siali-
dase activity, has a notably similar activity profile relative to the
control influenza B virus NA. Cleavage of the sialic acid residue
on this gangliosidic receptor by the WSEIV NA was also con-
firmed. Additional functional characterization further reinforces
this dichotomous nature of the HA and NA. Overall, we show
that this WSEIV is indeed a bona fide influenza virus from a
functional standpoint. We also address the antigenic conservation
of the WSEIV HA and NA using a panel of broadly cross-reactive
monoclonal antibodies (mAbs) and a set of serum samples from
humans positive for the influenza B virus.
Results
Representative HA and NA amino acid sequences of influenza A
and B viruses were selected and phylogenetically compared to
the WSEIV HA and NA. Along the lines of the whole virus
genome alignments in the study identifying this virus, we
observed the proximal clustering of the WSEIV HA and NA to
influenza B virus HAs and NAs (Fig. 1A, E). This encompasses
the seasonal vaccine strains from the two influenza B virus
antigenic lineages, B/Victoria/2/1987-like and B/Yamagata/16/
1988-like, and the ancestral pre-divergence B/Lee/1940 virus
too11. The sequences of each glycoprotein were superimposed
onto the publicly available structure of influenza B/Brisbane/60/
2008 virus counterparts to visualize where the ~45% (HA) and
~48% (NA) identity is present (Fig. 1B, F). As a comparative
control, influenza B/Malaysia/2506/2004 (part of the B/Victoria/
2/1987-like lineage) virus was selected and the HA and NA of this
virus were used for the experiments detailed in this study. These
glycoproteins have previously been expressed in our laboratory at
high yields and purity. We are also equipped with a mouse-
pathogenic B/Malaysia/2506/2004 challenge virus and reverse
genetics system for possible future research avenues to study the
WSEIV HA and NA. A pair-wise alignment of the WSEIV HA
and NA with the influenza B/Malaysia/2506/2004 virus HA and
NA was carried out (Fig. 1C, G). In the context of the HA, there
appeared to be mismatches in the residues that constitute the
sialic acid interacting receptor binding site12,13. This lack of
conservation was indicative of a potentially altered receptor
binding profile of the WSEIV HA. Additionally, the WSEIV HA
also appeared to have a reduced number of putative N-linked
glycosylation sites as identified by the consensus sequence N-X-
(S/T). The reduced glycosylation on the WSEIV HA relative to
the influenza B/Malaysia/2506/2004 HA was confirmed using a
deglycosylation assay with the respective recombinant proteins. A
larger difference in molecular weight was observed on a reducing
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE) gel for the B/Malaysia/2506/2004 HA pre- and
post-deglycosylation in comparison to the WSEIV HA (Fig. 1D).
From an antigenic standpoint, the target epitope of the pan-
influenza virus HA mAb, CR9114, was found to have some
mismatches too14. A large number of matched residues, however,
appear to be in the stalk domain of the HA, consistent with
previous studies showing higher levels of conservation in this
region across all influenza virus HAs15. Significant mismatches
were observed in the region immediately upstream to the fusion
peptide, largely conserved, encompassing the proteolytic cleavage
site essential for activation of the HA. The comparison of the NA
sequences, on the other hand, demonstrated a conserved enzy-
matic active site, as are the regions in its immediate vicinity. A
deglycosylation analysis of the B/Malaysia/2506/2004 and WSEIV
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NA did not reveal any overt differences in glycosylation patterns
across the glycoproteins with comparable shifts in molecular
weights pre- and post-deglycosylation (Fig. 1H).
The WSEIV HA and NA were studied and characterized in the
form of recombinant proteins as opposed to in a viral backbone
for several reasons. The available sequences for these proteins
comprised only the coding regions from the study identifying
them. Consequently, the packaging sequences in the non-coding
regions essential to rescuing these glycoproteins in an influenza B
virus backbone were not available. More importantly, introducing
novel glycoproteins into a known human pathogen, e.g. a human-
adapted influenza B virus backbone possesses a biosafety risk. As
Fig. 1 Comparative sequence analysis of the WSEIV glycoproteins. Phylogenetic trees based on the amino acid sequences of the WSEIV glycoproteins
and the representative influenza A and B HAs (A) and NAs (E) obtained from GISAID are shown. The scale bar indicates a 5% difference in amino acid
sequence. Amino acid conservation of the WSEIV HA (B) and WSEIV NA (F) relative to influenza B virus HA and NA are represented by the residues
highlighted in red. The structure and sequence of influenza virus strain B/Brisbane/60/2008 were used as a template for comparison. Pairwise alignments
of the WSEIV HA and NA are displayed against influenza B/Malaysia/2506/2004 virus HA and NA, (C) and (G), respectively. Identical residues are
indicated by asterisks. Functionally and antigenically relevant features have been annotated. Recombinantly expressed HAs (D) and NAs (H) of influenza
B/Malaysia/2506/2004 virus and WSEIV were visualized on an SDS–PAGE gel in deglycosylated and non-deglycosylated conditions. A representative of
two independent assays is shown. Structures are based on PDB# 4FQM50 for HA and PDB# 4CPL51 for NA.
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a result, these proteins were studied in a recombinant form to
ensure to meet safety concerns. The B/Malaysia/2506/2004 and
WSEIV HAs and NAs were expressed using a baculovirus
expression system as previously described16. Since the available
sequence for the WSEIV HA consisted of a truncated signal
sequence, a full-length signal peptide from the B/Malaysia/2506/
2004 virus HA was added instead. A C-terminal T4 trimerization
domain was used to ensure the expression of the HAs in their
native trimeric state. An N-terminal vasodilator stimulating
phosphoprotein (VASP) tetramerization domain was used to
maintain tetrameric structures of the respective neuraminidases.
To determine whether the WSEIV HA is capable of hemag-
glutinating erythrocytes, a conventional hemagglutination assay
was carried out. Recombinant WSEIV and B/Malaysia/2506/2004
HA were incubated with 0.5% chicken and turkey erythrocytes
starting at a concentration of 10 µg of recombinant HA. The B/
Malaysia/2506/2004 HA caused hemagglutination of both
chicken and turkey RBCs while an absence of hemagglutination
was observed with the WSEIV HA at the same concentrations
(Fig. 2A). Although this has been observed for recent H3N2 virus
isolates, we were intrigued by the lack of hemagglutination and
questioned the receptor usage of the WSEIV HA17. The receptor
binding specificity of the hemagglutinin protein of influenza
viruses is a vital parameter in addressing the potential of these
viruses to cross species barriers and determining host and tissue
tropism for infection18. Glycan arrays are an instrumental tool in
identifying the target receptor specificity for influenza virus HAs
in determining whether they preferentially bind to α2,3-linked or
α2,6-linked sialic acid receptors. We took advantage of this
approach to further interrogate interactions between WSEIV HA
and its potential binding partners. As a control, the recombinant
H5 HA from A/Vietnam/1203/2004 H5N1 influenza A virus,
influenza B/Malaysia/2506/2004 virus rHA, and the WSEIV rHA
were applied to a glycan array comprising of a variety of asialo,
α2,3-linked, α2,6-linked and gangliosidic structures (Fig. 2B). All
recombinant HAs were probed with a fluorescently tagged anti-
hexahistidine antibody to determine the extent of binding to
different glycans present on the array. In line with previously
published receptor specificity profiles for avian HAs, the H5 rHA
preferentially and predominantly binds to α2,3-linked sialic acids
present on the array19. The rHA of influenza B/Malaysia/2506/
2004 virus shows binding to both α2,3-linked and α2,6-linked
sialic acids, which has previously been attributed to the presence
of a Phe95 residue in influenza B virus HA as opposed to a
conserved tyrosine residue at the same site in influenza A
viruses20,21. The WSEIV HA showed a unique binding profile on
the glycan array (Fig. 2B), no binding was observed to α2,3-linked
or α2,6-linked sialic acids of increasing length as seen for the
influenza B virus HA. Strong fluorescence intensity indicative of
binding was observed on a singular spot on the array corre-
sponding to a ganglioside oligosaccharide, GM2. This mono-
sialylated ganglioside has an α2,3-linked sialic acid at the
penultimate galactose residue. To validate this interaction of the
WSEIV HA and GM2, bio-layer interferometry was applied to
determine a dissociation constant (Kd) and thereby binding affi-
nity (Fig. 2C). To do so, Ni-nitriloacetic acid (Ni-NTA) sensors
were loaded with fixed concentrations of hexahistidine-tagged
rHA proteins (10 µg/ml) and dipped in 1.5× fold serial dilutions
of recombinant GM2 starting at 100 µM. After ensuring that the
sensors were loaded to saturation with the hexahistidine-tagged
HAs, the association and dissociation kinetics of the HA–GM2
interaction were studied. An A/flat-faced bat/Peru/033/10 H18
hemagglutinin was applied as a negative control given its
unconventional nature to interact with MHC class II as receptors
for entry as opposed to sialic acid residues22. No binding
was observed for the H18 rHA and as observed previously in the
glycan array, B/Malaysia/2506/2004 rHA also showed no binding
to GM2. The WSEIV HA on the other hand shows excellent
association and dissociation profiles in a biphasic fashion with
GM2 in a dose-dependent manner. Analysis of this binding
allowed us to determine the Kd value of this interaction at
7.36 × 10−7 M, in the micromolar range, with R2 and χ2 indi-
cating good curve fits. These findings indicate and validate that
the GM2 ganglioside is a target receptor for this WSEIV HA.
Evidently, the WSEIV HA has a contrasting sialic acid-binding
profile in comparison to the influenza B virus rHA control.
Typically, following the receptor interaction of the HA with
sialic acid, the HA mediates membrane fusion of the influenza
virion allowing for the subsequent steps of infection and repli-
cation to occur. However, this requires the HA to be fusion
competent, a state that is reliant on host cell protease-mediated
activation. Cleavage by host proteases at the target site on the HA
upstream of the fusion peptide splits the HA0 precursor into the
HA1 and HA2 polypeptides23. Recently, a study dissected the
difference in preferential proteolytic cleavage of influenza A and
influenza B virus HAs by human airway proteases24. This is
crucial in addressing host adaptation of HAs and instrumental in
the crossing of species barriers with relative ease as observed with
highly pathogenic avian influenza viruses containing a polybasic
cleavage site, resulting in easier cleavage and priming of the HA
by furin-like proteases25. Influenza B virus HAs have been found
to be cleaved by a broad range of human airway proteases
belonging to the type II transmembrane serine protease and
kallikrein protease families24. We assessed the extent to which
these proteases can cleave the WSEIV HA (Fig. 2D). Human
embryonic kidney (HEK) 293T cells were co-transfected with
pCAGGS expression plasmids encoding for either the WSEIV or
the B/Malaysia/2506/2004 HA and pcDNA expression plasmids
encoding individual human airway proteases. The proteases
selected here have been previously shown to cleave influenza B
virus HAs24. As an untreated control, HEK293T cells were
transfected only with pCAGGS expression plasmids encoding
the respective HAs. N-tosyl-L-phenylalanine chloromethyl ketone
(TPCK)-treated trypsin was used as an additional control, with
pCAGGS HA-transfected cells being incubated with exogenous
trypsin briefly prior to harvesting of the cells. Cleavage of HA0
was detected through Western blotting after running the trans-
fected cell lysate on a reducing sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) gel. A
pool of monoclonal antibodies that are broadly cross-reactive to
influenza B virus HAs and polyclonal sera raised against the
WSEIV rHA in mice were used to detect cleavage of the B/
Malaysia/2506/2004 HA and WSEIV HA, respectively. Proteo-
lytic cleavage of the B/Malaysia/2506/2004 HA was detected to
varying extents with this panel of human airway proteases, evi-
denced by the presence of the HA1 bands (~50 kDA) in addition
to the HA0 bands (75 kDA). Strikingly, none of the selected
human airway proteases were able to cleave and activate the
WSEIV HA. HA1 was detectable only in the trypsin treated
sample (Fig. 2D). To determine whether the WSEIV HA is
fusogenic, a polykaryon formation assay was performed at dif-
ferent pH conditions. HeLa cells were transfected with pCAGGS
expressing the WSEIV HA. Following trypsin treatment to acti-
vate the HAs expressed on the cell surface, the cells were exposed
to different pH conditions and incubated for 4 h to allow fusion
to occur. Visualization of the cells at different pH conditions
showed the presence of polykaryons at a variety of different pHs
tested from pH 4.5 to 5.9 (Fig. 2E). No polykaryons were formed
at a control pH of 7.4 or in untransfected cells. Overall, this result
supports the notion that the WSEIV HA is functionally divergent
from the influenza B virus HA. The WSEIV HA interacts with a
unique GM2 gangliosidic receptor, is not activated by human
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airway proteases, and is fusogenic at a wide range of pH
conditions.
Given that the primary active site residues crucial for the sia-
lidase activity of the NA are conserved, we tested the functional
activity of the WSEIV NA. To do so, a conventional enzyme-
linked lectin assay (ELLA) was carried out using fetuin as a
substrate (Fig. 3A). Recombinant NAs were applied in 3-fold
serial dilutions starting at 15 µg/ml and the extent of NA activity
was determined based on the extent of sialic acid cleavage,
detected by binding of peanut agglutinin lectin to exposed
galactose residues. The overnight incubation of the rNA with
fetuin was carried out at four different temperatures, 4, 20, 33,
and 37 °C to determine the temperature dependence of the NA
activity. These were selected to encompass the possible
temperatures encountered by the spiny eels in their freshwater
environment in the Wuhan area. Given that the enzymatic
activity of the influenza B NA is understudied, an N9 rNA from
the A/Anhui/1/2013 H7N9 virus was used as a comparative
control. The major observation was that the WSEIV NA does
indeed have neuraminidase activity (Fig. 3A). This enzymatic
activity is also starkly similar to that of the B/Malaysia/2506/2004
NA at the tested temperatures. Preliminary analysis suggests that
the N9 rNA appears to have higher enzymatic activity compared
to both the influenza B virus and influenza B virus-like NAs. To
better understand the temperature dependency, the specific
activity of the NA was determined using the inverse of the half-
maximum lectin binding. As expected, we observe a step-wise
reduction in the activity of each NA at lower temperatures. The
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specific activity profile is also almost identical for the WSEIV NA
and the B/Malaysia/2506/2004 NA.
Keeping in mind the novel aspect of the WSEIV NA recently
identified in a non-human host, we investigated its potential
sensitivity to the NA inhibitor such as oseltamivir (Tamiflu),
peramivir or zanamivir (Fig. 3B). This was tested using a neur-
aminidase inhibition ELLA assay wherein fixed concentrations of
rNAs were pre-incubated with oseltamivir starting at 156.28 µM
and serially diluted two-fold prior to being transferred onto fetuin
coated plates. The extent of inhibition was estimated by increased
lectin binding with lower oseltamivir concentrations. The WSEIV
NA was sensitive to oseltamivir, and the dose dependency was
identical for all the tested recombinant NAs (Fig. 3B). Similar
results were obtained with peramivir and zanamivir although
these drugs showed higher potency than oseltamivir. These
findings also align with the aforementioned observation that the
active site of the WSEIV NA and the surrounding regions are well
conserved to the B/Malaysia/2506/2004 NA allowing for the
binding and inhibition by NA inhibitors.
To follow up on the unique receptor binding profile shown by
the WSEIV HA, we questioned whether the WSEIV NA has
altered substrate specificity compared to the B/Malaysia/2506/
2004 NA (Fig. 3C). To probe this, ELLAs were carried out as
previously described in a study looking at N9 NA in H7N9
influenza A viruses26. Lectins with different binding specificities
were used to determine if the NAs preferentially cleaved α2,3-
linked or α2,6-linked sialic acids using fetuin as a substrate which
carries both these linkages in a 2:1 ratio27. Specifically, Erythrina
crista-galli (ECA), peanut agglutinin (PNA), Maackia amurensis
lectin I (MALI), and Sambucus nigra lectin (SNA) were used.
ECA and PNA both have been found to show binding to non-
siaylated N- and O-linked sugars respectively, hence their binding
would be higher in the presence of a NA28,29. MALI and SNA
preferentially bind only α2,3- and α2,6-linked sialic acids,
respectively, and their binding decreases with NA cleavage of the
target substrates30,31. As described earlier, the specific activity of
the NA was determined and normalized to that seen with fetuin-
ECA for each NA. In line with the enzymatic activity, the WSEIV
and B/Malaysia/2506/2004 NA have equivalent substrate speci-
ficities, with both having comparable cleavage profiles (Fig. 3C).
Although a similar conclusion can be drawn for the A/Anhui/1/
2013 N9 neuraminidase, this preferential cleavage appears to be
more polarized. Subsequently, we characterized the kinetics of the
enzymatic reactions of these NAs, i.e. do these NAs have com-
parable enzyme kinetics despite having similar temperature-
dependent activity and substrate specificity? To investigate this,
we derived the Michaelis–Menten parameters, Vmax and Km, from
the NA–sialic acid enzyme–substrate reaction (Fig. 3D). At a
fixed concentration, rNAs were incubated with the fluorogenic 4-
methylumbelli-feryl N-acetyl-α-D-neuraminic acid (MUNANA)
substrate and the relative fluorescence readings were taken every
90 s for 40 min as previously described32. The velocity of the
reactions were determined for each concentration of MUNANA
(starting at 1000 µM) and accordingly the Vmax and Km were
calculated. The maximum enzymatic activity, Vmax, for both the
WSEIV and B/Malaysia/2506/2004 NA are similar to each other,
and they both display a high affinity for the MUNANA substrate
(indicated by the 1/Km). The N9 rNA shows exponentially higher
maximum enzymatic activity and a markedly lower affinity for
the substrate, which could possibly explain the stronger specific
activity seen earlier while measuring substrate affinity.
The neuraminidase plays a crucial role in the viral life cycle in
the context of facilitating viral egress and release through the
cleavage of sialic acid bound to the viral HA. This allows for
productive infection cycles in the host. In context of WSEIV, this
would require the NA-mediated cleavage of the α2,3-linked sialic
acid residue on the cognate GM2 receptor of the WSEIV HA. To
determine whether the WSEIV NA possesses this ability, a free
sialic acid assay and a thin layer chromatography-based approach
were used in parallel. Recombinant GM2 was incubated with the
WSEIV NA and the free sialic acid content was evaluated using a
commercially available kit. As a negative control, GM2 was
incubated with an irrelevant protein (bovine serum albumin).
Fetuin incubated with WSEIV NA was used as a positive control.
Cleavage of the sialic acid on GM2 was observed as determined
by the presence of free sialic acid (Fig. 3E). This was also visua-
lized following thin-layer chromatography wherein GM2 incu-
bated with WSEIV NA ran further on the chromatogram in
comparison to untreated GM2 or GM2 treated with BSA
(Fig. 3F). Fetuin incubated with WSEIV NA was not visualized on
this chromatogram given the higher molecular weight of fetuin
compared to GM2, and hence the lack of migration following
sample spotting.
Having characterized the functionality of the WSEIV HA and
NA, we focused on surveying the extent to which broadly cross-
reactive epitopes identified on influenza B virus HAs are con-
served on these glycoproteins (Fig. 4A, B). Probing of the WSEIV
HA and NA was carried out using a panel of broadly cross-
reactive human and mouse monoclonal antibodies (mAbs) pre-
viously characterized to bind to both antigenic divergent and
ancestral lineages of influenza B viruses14,33–37. Control enzyme-
linked immunosorbent assays (ELISAs) were performed for these
mAbs against the influenza B/Malaysia/2506/2004 virus HA and
NA and robust binding profiles for most of the tested antibodies
Fig. 2 The WSEIV HA has a divergent functional profile relative to the influenza B/Malaysia/2506/2004 virus HA. A Recombinant HA proteins
starting at 10 µg serially diluted two-fold were applied in a classical hemagglutination assay with 0.5% chicken or turkey erythrocytes. B Receptor binding
specificity of the WSEIV HA was determined using a glycan microarray. A/Vietnam/1204/2004 H5 and B/Malaysia/2506/2004 HAs served as controls
to compare binding profiles of the HAs. Glycans 1-4 represent asialic structures with the indicated backbones. Glycans 5-8 and 9-12 are α2,3- and α2,6-
linked sialic acid glycans, with A–L comprising complex glycans and gangliosides. A simplified structure of the GM2 ganglioside, sample B on the array is
shown. The mean signal for each glycan–HA binding is shown with each glycan printed in replicates of 6. Error bars indicate standard deviation and
technical replicates were performed. The binding was confirmed with two separate batches of recombinant WSEIV HA. C The WSEIV HA–GM2
ganglioside interaction was validated by bio-layer interferometry. B/Malaysia/2506/2004 HA and H18 HA were used as negative controls with expected
absence of binding towards GM2. The association and dissociation kinetics curve fits of the interaction are shown and the dissociation constant (Kd) was
calculated accordingly. D Western blotting was performed to determine the proteolytic cleavage profile of the WSEIV and B/Malaysia/2506/2004 HAs
by human airway proteases. Cell lysate was generated following co-transfection with pCAGGS HAs and pcDNA3.1 protease expressing plasmids. HA1 was
detected as a marker for proteolytic cleavage alongside uncleaved HA0. Cells transfected with pCAGGS HA either untreated or exposed to TPCK-treated
trypsin served as controls for proteolytic cleavage. Representative images of two independent assays are shown. E A polykaryon formation assay was
applied to determine the fusogenicity of the WSEIV HA. HeLa cells transfected with the pCAGGS WSEIV HA were treated with TPCK-treated trypsin,
exposed to different indicated pH conditions, and allowed to recover to determine for cell-to-cell fusion. This assay was performed in independent
duplicates and a representative image is shown.
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were observed. Five antibodies showed strong binding to the
WSEIV HA, namely, 1B5, 4C10, 8G3, 9B9, and 11C12 (all murine
mAbs, Fig. 4A). With the exception of 1B5, all these mAbs bind
to linear epitopes on the conserved long alpha helix in the stalk
domain of the influenza B virus HA33. As stated earlier, con-
servation between the WSEIV and B/Malaysia/2506/2004 HA (or
influenza B virus HAs at large) is relatively high in this region
(Fig. 1B, C). No binding of the pan-influenza virus HA human
mAb CR9114 was detectable, as anticipated from the mismatches
in the binding epitope of the antibody14. The binding of CR9114
to influenza B virus HA was low but detectable. Of the panel of
human and mouse mAbs used to probe the WSEIV NA, only one
antibody showed detectable and strong binding (Fig. 4B). This
human mAb, 1G01, has been characterized to have a target
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binding epitope in the active site of the NA facilitated by a long
heavy chain CDR3 loop. Consequently, the breadth of the anti-
body encompasses influenza A and B virus NAs, showing neur-
aminidase inhibition activity against most of the tested influenza
virus NAs35. Overall, we observe an interesting profile for the
WSEIV HA and NA from an antigenic standpoint. For a func-
tionally dissimilar WSEIV HA, there are a larger number of
conserved epitopes distributed in the stalk domain. Conversely,
identical functionality seen for the WSEIV NA with B/Malaysia/
2506/2004 NA is accompanied by an absence of this conservation
outside of the enzymatic active site pocket (Fig. 1E, F). Addi-
tionally, serum samples from humans post-seasonal influenza
vaccination (collected between 2017 and 2019) were used in
ELISAs against the WSEIV HA and NA (Fig. 4C). This was done
to identify basal or pre-existing cross-reactive immunity against
the WSEIV HA or NA in humans as a consequence of seasonal
vaccination or prior influenza virus infection. Safely assuming
immunological naivety, a recombinant glycoprotein from Mopeia
virus, belonging to the arenavirus family, was used as a target
antigen in ELISAs to establish baseline reactivity in our assay. No
pre-existing immunity or post-vaccination-induced antibodies
were detected against the WSEIV HA or NA further reinforcing
the limited conservation of broadly cross-reactive target epitopes
as determined by the panel of mAbs earlier.
Discussion
Here, we have characterized the putative HA and NA of the Wuhan
spiny eel influenza virus, an influenza B-like virus identified via
sequence analysis in lesser spiny eels. The two studies that identified
the WSEIV and a salamander influenza-like virus that also clusters
close to influenza B viruses discuss the occurrence of prolonged
virus–host co-divergence with several host-switching events over
time9,38. Largely, influenza B viruses have been discounted from
being a pandemic threat due to the absence of an identified sustained
non-human reservoir. Co-circulating influenza B viruses in humans
have been shown to have reassortment potential within the two
antigenic lineages, with B/Victoria/2/87-like viruses acquiring gene
segments from B/Yamagata/16/88-like viruses39. Taken together, this
strengthens the unmet need for studies characterizing novel influenza
B-like viruses in undersampled hosts and subsequently under-
standing the functionalities of these understudied viruses. Consider-
ing that vaccine approaches towards influenza viruses predominantly
target the dominant HA - and more recently the NA - surface gly-
coproteins, it is vital to have a comprehensive understanding of these
proteins of influenza B-like viruses too40. In addition, our char-
acterization of the B/Malaysia/2506/2004 HA and NA also supple-
ments existing literature on influenza B virus glycoproteins which is
finite in contrast to studies addressing influenza A viruses.
Along with showing limited antigenic conservation, we demon-
strate that the WSEIV HA interacts with an a-series ganglioside,
GM2, as a target receptor. Although GM2 has been identified as an
interacting partner for some reoviruses and rotaviruses, it has been
shown to be not recognized by influenza A viruses, with studies
demonstrating that gangliosides are entirely non-essential for influ-
enza virus entry41–44. As a therapeutic target, overaccumulation of
GM2 on neuronal cells has been implicated in Tay Sachs and
Sandhoff diseases with mutations rendering hexosaminidases non-
functional45. GM2 overexpression is also observed in a variety of
human cancers and has been linked with increased tumor angio-
genesis and metastatic potential46,47. The WSEIV HA also appears
not to bind to GM1a or GM3 as observed from the glycan array
binding analysis. The receptor binding also seems to rely on the
terminal GalNAc residue given that the loss of this in GM3 is
accompanied by abrogation in binding. The location of the α 2,3-
linked sialic acid residue in GM2 appears to be crucial as no binding
is seen to a galactose extended GM1a ganglioside. From the per-
spective of gene therapy, having a viral glycoprotein that selectively
targets this ganglioside could prove to be instrumental when pseu-
dotyped into viral vectors for gene delivery. In an aquatic setting,
GM2 has been found to be over-expressed in gills, brain, heart, and
reproductive organs of fish (zebrafish) corroborating the discovery of
the WSEIV in the gills of lesser spiny eels48. For the WSEIV NA, our
findings highlight the strong conservation of enzymatic activity and
kinetics, substrate specificity, and neuraminidase inhibitor sensitivity
with the corresponding influenza B virus NAs. Especially the similar
temperature profiles of WSEIV and influenza B virus NAs are
interesting since the expectation was that the WSEIV NA would be
more active at lower temperatures as found in the habitat of the lesser
spiny eel. This also raises the possibility that the WSEIV is actually of
mammalian or avian origin. Additional studies are needed to further
determine if the virus is a bona fide fish virus or if it originated from
other, warm-blooded animals.
The abundant expression of GM2 across different organs in zeb-
rafish supports the possibility that the WSEIV could infect other
species of fish as well. Consequently, human infection could occur
with individuals directly interacting with these aquatic species at, e.g.
at commercial fisheries or aquaria as well as during recreational
fishing or swimming. The lesser spiny eel (M. aculeatus) and other
Macrognathus species are distributed throughout Southeast Asia and
are farmed and harvested for food49. Of note, GM2 is of course also
present in humans. In addition, we found very limited antigenic
similarity between WSEIV and influenza B virus glycoproteins.
Cross-reactivity of mAbs was limited to a small subset of antibodies
and no cross-reactivity was found in human serum suggesting that
humans are immunologically naïve to the WSEIV glycoproteins.
In summary, the WSEIV HA and NA proteins show varying
degrees of similarity to their influenza B virus counterparts. The
HA displays sialic acid binding activity specifically towards GM2
and thereby differs substantially from known influenza A and B
virus HAs, and the NA is indeed a sialidase with very similar
Fig. 3 Functionally, the WSEIV NA is strikingly similar to the influenza B/Malaysia/2506/2004 virus NA. A Sialidase activity of recombinant WSEIV,
influenza B/Malaysia/2506/2004 and A/Anhui/1/2013 H7N9 NA proteins was evaluated in an enzyme-linked lectin assay using fetuin, at four
temperatures; 4, 20, 33, 37 °C. The curves indicate absorbance measured at 490 nm with error bars indicating standard deviation. Specific enzyme activity
(inverse of half-maximum lectin binding) determined by these absorbance curves are shown for each individual NA at each temperature. B Susceptibility to
NA inhibitors was tested in an ELLA-based neuraminidase inhibition assay . Error bars indicate standard deviation. Absorbance at 490 nm based on lectin
binding was measured with increasing concentrations of oseltamivir, peramivir or zanamivir. C Neuraminidase substrate specificity was assessed using an
ELLA with fetuin and lectins with different specificities (ECA, PNA, SNA, and MALI). Specific enzyme activity was determined as described in (A) and it is
represented as a percentage normalized to fetuin-ECA. D Michaelis–Menten parameters, Vmax and Km, were estimated based on enzymatic activity of
recombinant NAs against MUNANA substrate. The A/Anhui/1/2013 N9 NA served as a comparative control for both the WSEIV and B/Malaysia/2506/
2004 NAs. E Cleavage of sialic acid on GM2 by the WSEIV NA was confirmed using an assay to measure free sialic acid content (sialic acid NANA assay
kit, Abcam). F Thin layer chromatography was used to visualize the presence of cleaved GM2 following treatment with the WSEIV NA. The arrow shows
the direction in which the chromatography was run. A representative image is shown after the assay was performed in independent duplicates. Technical
duplicates were performed once for (A–E).
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functionality compared to influenza B virus NA. The data pro-
vided in this study contribute to our overall understanding of
influenza B and influenza B-like viruses, and to understanding of
the pandemic potential of the influenza B-like viruses from non-
human reservoirs.
Methods
Cells and proteins. Human embryo kidney 293T cells were cultured in complete
Dulbecco’s modified Eagle medium (DMEM; Life Technologies) constituted by
DMEM supplemented with Pen-Strep antibiotics (100 U/ml penicillin, 100 µg/ml
streptomycin; Gibco), 10% fetal bovine serum (FBS, HyClone), and 10 ml of 1M 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Life Technologies).
Sf9cells (ATCC CRL-1711) and High Five cells (BTI-TN-5B1-4 subclone; Vienna
Institute of Biotechnology) were grown in Trichoplusia ni medium-formulation
Hink (TNM-FH) insect medium (Gemini Bioproducts) supplemented with Pen-
Strep and 10% FBS, and serum free medium (SFM) insect cell medium (HyClone),
respectively33.
The recombinant proteins used in this study (WSEIV HA, WSEIV NA, B/
Malaysia/2506/2004 HA, B/Malaysia/2506/2004 NA, A/Vietnam/1203/2004 H5
HA, A/flat-faced bat/Peru/033/2010 H18 HA, A/Anhui/1/2013 N9 NA) were
expressed and purified from High Five cell culture supernatant as described in
detail previously16.
Phylogenetic and comparative sequence analysis. Phylogenetic trees for the HA
and NA were generated as described previously33. Briefly, sequences were obtained
from the Global Initiative on Sharing All Influenza Data (GISAID), aligned using
Fig. 4 Epitopes that are broadly conserved in influenza B virus glycoproteins are largely absent the WSEIV HA and NA, with cross-reactivity
being mostly restricted to the stalk domain of the HA and active site of the NA. A and B Binding profiles of broadly cross-reactive anti-influenza B virus
HA and NA human (H) and mouse (M) monoclonal antibodies in ELISAs are shown against recombinant B/Malaysia/2506/2004 and WSEIV HA and
NAs. 4F11 (anti-influenza B virus NA) and 4C2 (anti-influenza B virus HA) mouse mAbs were used as negative controls for the ELISAs against the HAs and
NAs respectively. C Presence of pre-existing immunity or induction of cross-reactive antibodies against the WSEIV HA and NA was evaluated through
ELISAs using human serum samples obtained post-seasonal influenza vaccination (n= 18). Mopeia virus glycoprotein was used as a negative control for
baseline establishment, and area under the curve was calculated with a cutoff of average plus three times the standard deviation of the blank wells. The
geometric mean for each group is indicated with a line. Experiments were performed once in technical duplicates.
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Clustal Omega (v1.2.4), and the phylogenetic trees were generated using FigTree
(v1.4.3). The annotation of the tree was carried out in Adobe Illustrator CS5.1.
Pairwise alignment of the WSEIV HA and NA (MG600041.1 and MG600042.1)
and B/Malaysia/2506/2004 HA and NA (CY040449.1 and CY040451.1) was per-
formed using Clustal Omega v1.2.4, following which the features of note were
labeled in Adobe Illustrator CS5.1. For the rendered model of glycoproteins dis-
playing sequence conservations, the WSEIV HA and NA were aligned pairwise
against the B/Brisbane/60/2008 HA and NA. The alignment was superimposed on
the B/Brisbane/60/2008 HA and NA structures publicly available on PDB (HA:
4FQM50; NA: 4CPL51) using UCSF Chimera.
SDS–PAGE and Western blotting. Recombinant proteins (10 µg) were applied to
4–20% gradient polyacrylamide gels (Bio-Rad) after heating them for 20 min at
95 °C in 2× Laemmli buffer with 2% β-mercaptoethanol (BME). SDS–PAGE was
performed at 200 V for 35 min following which the gels were stained with Sim-
plyBlue Safe Stain (Thermo Fisher) to visualize the bands alongside a color pre-
stained protein broad range standard (New England Biolabs). Deglycosylation was
carried out using the Protein Deglycosylation Mix II (New England Biolabs) as per
the manufacturer’s instructions.
Western blotting procedures to determine the proteolytic cleavage of the HA
were carried out as previously described24,33. HEK293T cells were co-transfected
with pCAGGS expression plasmids encoding for the corresponding HA and
pcDNA3.1 plasmids encoding human airway proteases (Genscript). The Western
blotting procedure was carried out with cell lysates, probing with either polyclonal
sera raised against the WSEIV HA in female BALB/c mice (at a dilution of 1:100)
or with a pool of anti-influenza B virus HA mAbs (at 10 µg/ml) characterized in
this ref. 33.
Hemagglutination assay. Recombinant HA starting at 10 µg diluted serially 2-fold
was incubated with 0.5% chicken or turkey erythrocyte suspension and incubated
at 4 °C for an hour. The plates were then scanned to determine the extent of
hemagglutination of these erythrocytes.
Glycan array. Glycan array binding analysis of the rHAs was carried out as
described here52,53. Briefly, recombinant hexahistidine-tagged HA was pre-
complexed with a mouse anti-his Alexa 647 (antibody mouse anti-his 647 anti-
body, Abcam, ab237337, clone EPR20547) and goat-anti-mouse Alexa 647
antibodies (Thermo, Cat # A28181; RRID: AB_2536165). This was done in 50 µl
PBS-T (phosphate-buffered saline with 0.1% Tween-20) in a 4:2:1 molar ratio,
incubated for 15 min on ice, and the applied on the array for 90 min in a humi-
dified chamber. Following multiple washes with PBS-T, PBS, and deionized water
the arrays were scanned to detect HA binding. Mean RFU and standard deviation
values were imported into Prism 7.0 and the corresponding graph was generated.
Bio-layer interferometry. As described previously, biolayer interferometry with an
Octet Red96 instrument (ForteBio) was used to determine the dissociation constant
of the HA-GM2 receptor interaction54. Recombinant hexahistidine-tagged HAs at
10 µg/ml was loaded onto Ni-NTA biosensors (Fortebio) for 780 s to ensure
saturation after a baseline step was established for 60 s. A second baseline was
established post-loading spanning 120 s. Then the association (300 s) and dis-
sociation (900 s) kinetics were recorded as the HA-loaded sensors were dipped into
1.5-fold serially diluted concentrations of recombinant GM2 (Sigma Aldrich). The
reaction was carried out in a 1× kinetics buffer comprising of 1× PBS, 0.01% bovine
serum albumin (BSA) and 0.002% Tween 20. The dissociation constant was cal-
culated accordingly using the suitable model for a biphasic association and dis-
sociation profile, and global curve fit was applied to all the sensors. Octet Red96
Data Acquisition v12.0 software was used to acquire the biolayer-
interferometry data.
Fusion assay. A polykaryon formation assay to determine the fusogenicity of the
WSEIV HA was performed as described in detail previously24. HeLa cells (CCL-2,
ATCC) were seeded in 96-well tissue culture plates (Corning) and transfected with
a pCAGGS plasmid expressing the WSEIV HA. The following day, the cells were
washed with Dulbecco’s phosphate buffer saline (DPBS), exposed to TPCK-treated
trypsin at 5 µg/ml for 15 min, washed with DPBS, and subsequently exposed to pH
adjusted DPBS ranging from pH 4.5 to 5.9 adjusted with citric acid. After 15 min of
an acid pulse, the cells were washed and allowed to recover and fuse in complete
DMEM for 4 h. The cells were then fixed with 3.7% paraformaldehyde in PBS and
permeablized with 0.1% Triton X-100 for 15 min each. All of these steps were
performed at 33 °C. Staining was performed using the HCS Cell Mask Green (Life
Technologies) as per manufacturer’s instructions for 30 min at 5 µg/ml. Imaging
was performed using EVOS FL Cell Imaging microscope (Thermo Fisher) and the
images were collectively processed using Adobe Photoshop and annotated using
Adobe Illustrator.
ELLAs. ELLAs were performed as described in detail previously to determine the
enzymatic activity of the NAs or the NA inhibitor sensitivity of the NAs55. Briefly,
Immulon 4 HBX plates (Thermo Scientific) were coated with 100 µl/well of fetuin
(Sigma) at 25 µg/ml overnight at 4 °C. The fetuin-coated plates were incubated with
2 fold dilutions of recombinant NAs starting at 10 µg/ml in 5% BSA in PBS
overnight at the indicated temperatures. The following day, the plates were washed
three times with PBS-T and were incubated with 5 µg/ml of peanut agglutinin
conjugated to horseradish peroxidase (PNA-HRP) for two hours at room tem-
perature. The plates were washed with PBS-T three times and developed with
100 µl of Sigmafast o-phenylenediamine dihydrochloride (OPD) (Sigma Aldrich).
The only applied variation was that the overnight incubation was carried out at
four different temperatures (4, 20, 33, and 37 °C) to determine the temperature-
dependent profile of the NAs. When oseltamivir, zanamivir, and peramivir were
used, the starting concentration applied was 156.28 µM with 2-fold serial dilutions,
and they were pre-incubated with the recombinant NAs for 1 h shaking at 37 °C
after which the conventional ELLA protocol was followed. Substrate specificity
characterization and specific enzyme activity determination was performed in
ELLA assays identical to that described in ref. 26. Absorbance measurements were
carried out at 490 nm following the development with Sigmafast OPD, and the
specific enzyme activity (inverse of half-maximum lectin binding) was determined
following a non-linear regression analysis in Graphpad Prism 7, and was plotted
normalized to the fetuin-ECA to determine activity per amount of protein in
context of cleavage of α2,3 or α2,6-linked sialic acids.
Michaelis–Menten kinetics. Enzyme kinetics and the Michaelis–Menten para-
meters were determined as described previously32. Briefly, recombinant NAs at a
fixed concentration of 10 µg/ml were incubated with 1.5 fold dilutions of the
fluorogenic MUNANA substrate in MES (2-ethanesulfonic acid2-ethanesulfonic
acid) buffer with suitable blank controls for background fluorescence. The plates
were incubated at 37 °C and readings for relative fluorescence units (RFUs) were
recorded at every 90 s for 40 min using a Gen5 v3.0 Software and a Synergy H1
Microplate Reader (BioTek). The RFU readings were captured at excitation and
emission wavelengths of 360 and 448 nM. Velocity of the reaction was determined
by plotting the RFU readings against time, and the Michaelis–Menten parameters
Vmax and Km were determined through non-linear regression fits of the velocity
and MUNANA concentrations in Graphpad Prism 7.
Free sialic acid assay and thin layer chromatography. Recombinant GM2
(100 μM) was incubated with WSEIV NA or BSA at 10 μg/ml. As a positive control,
fetuin (100 μM) was incubated with WSEIV NA (10 μg/ml). The reactions were
then analyzed using a Sialic Acid (NANA) assay kit (Abcam) as per the manu-
facturer’s instructions. The amount of free sialic acid was determined by extra-
polation from a standard curve and graphed using Graphpad Prism 7. The same
samples were also applied using a 700 series microliter syringe (Hamilton) onto
pre-scored silica gel TLC plates (Millipore Sigma) and placed in a running buffer of
ethanol:acetic acid:water at 5:2:1. As a control for both experiments, GM2 was also
incubated with BSA as an irrelevant protein. Assay buffer without GM2 was also
applied to the TLC plate as a blank control. The plates were visualized using a Bio-
Rad Gel Doc (Bio-Rad), and the chromatogram was annotated on Adobe
Illustrator.
ELISAs. ELISAs were performed as previously described in detail33. Immulon 4
HBX plates (Thermo Scientific) were coated overnight with 2 µg/ml of recombinant
protein in 1× coating buffer (Seracare). The plates were blocked with 3% milk
powder in PBS-T for one hour at room temperature following which they were
incubated with 3-fold dilutions of mAbs starting at 30 µg/ml or human serum
samples at a dilution of 1:250 for two hours at room temperature. The plates were
washed three times with PBS-T and stained with the appropriate goat anti-human
(Invitrogen, 31410) or goat anti-mouse HRP-tagged (Rockland, 610-1302) anti-
body at a dilution of 1:3000 in PBS-T and developed using Sigmafast OPD.
Information surrounding individual antibodies used in the primary staining pro-
cedure are available in the cited references.
Human serum samples. Serum samples were obtained from healthy participants
participating in a longitudinal, observation, non-interventional study (STUDY-16-
01199, PI: V. Simon) approved by the Institutional Review Board of the Mount
Sinai School of Medicine. Informed consent was obtained prior to study partici-
pation and participants provided written permission to biospecimen banking and
future research use. Samples were collected between 2017 and 2019. All samples
were de-identified and analyzed in a blinded manner.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data are available in the manuscript or the supplementary materials. Source data are
provided with this paper. HA (4FQM) and NA (4CPL) structures for B/Brisbane/60/2008
were obtained from PDB. Sequences for the HAs and NAs for the phylogenetic trees were
obtained from GISAID (H1-H18: H1-H18: EPI1349891, EPI899625, EPI673678,
EPI1007628, EPI942074, EPI1154383, EPI1090164, EPI1154159, EPI1103524,
EPI953583, EPI774886, EPI1007631, EPI967018, EPI750076, EPI965435, EPI939704,
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-26409-2
10 NATURE COMMUNICATIONS |         (2021) 12:6161 | https://doi.org/10.1038/s41467-021-26409-2 | www.nature.com/naturecommunications
EPI356309, EPI486922; B/Lee/1940 HA: EPI243230; B/Phuket/3073/2013 HA:
EPI1799824; B/Colorado/06/2017 HA: EPI969380; N1-N11: EPI1381203, EPI899627,
EPI939823, EPI1154448, EPI1007658, EPI939830, EPI750078, EPI941550, EPI965439,
EPI356311, EPI356298; B/Lee/1940 NA: EPI366432; B/Phuket/3073/2013 NA:
EPI1799823; B/Colorado/06/2017 NA: EPI969379). WSEIV HA and NA (MG600041.1
and MG600042.1) and B/Malaysia/2506/2004 HA and NA (CY040449.1 and
CY040451.1) sequences were used for the pairwise alignment represented in
Fig. 1. Source data are provided with this paper.
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